Zacks Investment Research Downgrades Sunesis Pharmaceuticals (SNSS) to Hold

Share on StockTwits

Sunesis Pharmaceuticals (NASDAQ:SNSS) was downgraded by Zacks Investment Research from a “strong-buy” rating to a “hold” rating in a research note issued on Thursday.

According to Zacks, “Sunesis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. It has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. It is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies. “

Several other research analysts have also issued reports on the company. ValuEngine upgraded Sunesis Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, January 2nd. HC Wainwright initiated coverage on Sunesis Pharmaceuticals in a research report on Thursday, December 20th. They issued a “neutral” rating and a $0.50 price target on the stock. Five analysts have rated the stock with a hold rating, Sunesis Pharmaceuticals presently has an average rating of “Hold” and an average price target of $2.00.

NASDAQ:SNSS opened at $0.73 on Thursday. Sunesis Pharmaceuticals has a 12-month low of $0.20 and a 12-month high of $7.69. The firm has a market capitalization of $18.33 million, a PE ratio of -0.51 and a beta of 2.57.

Sunesis Pharmaceuticals (NASDAQ:SNSS) last posted its quarterly earnings results on Monday, November 5th. The biopharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.22) by $0.04. On average, research analysts anticipate that Sunesis Pharmaceuticals will post -0.81 earnings per share for the current fiscal year.

Sunesis Pharmaceuticals Company Profile

Sunesis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. Its lead program is vecabrutinib, a non-covalently binding inhibitor of Bruton's tyrosine kinase (BTK), which is in Phase 1b/2 clinical trial in B-cell malignancies.

See Also: Fundamental Analysis and Individual Investors

Get a free copy of the Zacks research report on Sunesis Pharmaceuticals (SNSS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Sunesis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Western Asset Global High Income Fnd Inc  Major Shareholder Saba Capital Management, L.P. Purchases 79,430 Shares of Stock
Western Asset Global High Income Fnd Inc Major Shareholder Saba Capital Management, L.P. Purchases 79,430 Shares of Stock
Shiloh Industries, Inc.  Expected to Announce Earnings of -$0.15 Per Share
Shiloh Industries, Inc. Expected to Announce Earnings of -$0.15 Per Share
e.l.f. Beauty Inc  Insider John P. Bailey Sells 86,600 Shares
e.l.f. Beauty Inc Insider John P. Bailey Sells 86,600 Shares
Safety Insurance Group  Stock Rating Lowered by BidaskClub
Safety Insurance Group Stock Rating Lowered by BidaskClub
Stitch Fix  Rating Increased to Buy at Zacks Investment Research
Stitch Fix Rating Increased to Buy at Zacks Investment Research
Silicon Motion Technology  PT Lowered to $45.00 at Roth Capital
Silicon Motion Technology PT Lowered to $45.00 at Roth Capital


Leave a Reply

© 2006-2019 Ticker Report